News

Abbott has received marketing authorisation from the European Commission for once-daily dosing of Kaletra (lopinavir/ritonavir) tablet, the company’s lead HIV protease inhibitor (PI), in adult patients new to

GlaxoSmithKline (GSK) has provided results from its first clinical trial assessing use of its pandemic (H1N1) adjuvanted vaccine. The results demonstrate that after one dose the candidate vaccine

Schering-Plough has reported long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the phase II VICTOR-E1 study in treatment-experienced HIV-infected patients. The

Inspire Pharmaceuticals has committed to increasing production of AzaSite in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%). The FDA has placed erythromycin ophthalmic ointment

Artielle ImmunoTherapeutics (Artielle) has provided the results of a phase 1 safety study of RTL1000, a recombinant T-Cell receptor ligand specific for an immunodominant MOG peptide, in multiple

Study demonstrating, Cardium’s Gene Activated Matrix or GAM technology accelerates periodontal tissue regeneration of oral implant-supporting wounds, was published in the scientific journal, Gene Therapy. According to Cardium,

Antisense Pharma (Antisense) has received orphan drug designation from both the European Medicines Agency (EMEA) and the FDA for its investigational drug, trabedersen, in the treatment of pancreatic

Kenta Biotech (Kenta) has provided positive phase IIa results of its lead drug candidate, panobacumab (KBPA101), showing it is safe and well tolerated in patients with hospital-acquired pneumonia

Rib-X Pharmaceuticals (Rib-X) plans to enter into a Clinical Trials Agreement with the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of